Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.19 +0.15 (+0.60%)

Official Closing Price Updated: 7:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

How Do Investors Really Feel About Pfizer? ↗

August 14, 2025

Via Benzinga

Cautious Start On Dalal Street As Traders Eye Expiry, WPI Inflation Data; Muthoot Hits Record High, Infosys Gains on Versent Deal ↗

August 14, 2025

Markets watch for the Trump–Putin meeting tomorrow that could impact Russia–Ukraine peace talks. Analysts see 24,600 as a make-or-break level for Nifty ahead of weekly expiry volatility.

Via Stocktwits

Topics Economy Government

Most active S&P500 stocks in Wednesday's session ↗

August 13, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer ↗

August 13, 2025

This big pharma company's juicy dividend is looking even more attractive.

Via The Motley Fool

Topics Earnings

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 13, 2025

Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year....

Via StockStory

Topics Earnings

PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty

August 13, 2025

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full...

Via StockStory

Topics World Trade

The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call

August 13, 2025

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance...

Via StockStory

Topics Earnings

Trading Radar For August 13: Paytm, HUL, Cochin Shipyard, Karnataka Bank, And Jindal Steel Are On Stocks Watchlist ↗

August 12, 2025

BPCL, Pfizer, Vishal Mega Mart, among others, are expected to post their quarterly earnings today.

Via Stocktwits

Topics Economy Energy

Pfizer Raises Its Guidance And Analysts Up Their Targets - PFE Stock Looks Cheap ↗

August 12, 2025

Pfizer, Inc. stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year.

Via Talk Markets

CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency ↗

August 12, 2025

CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.

Via Benzinga

Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued ↗

August 12, 2025

According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season.

Via Stocktwits

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy.

Via Benzinga

Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

August 12, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Got $1,000? 3 Dividend Stocks to Buy and Hold Forever ↗

August 12, 2025

Dip into a beaten-down market sector for deals on some proven winners.

Via The Motley Fool

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

August 12, 2025

From Pfizer Inc.

Via Business Wire

Trading Radar For August 12: Hindalco, Adani Enterprises, Bata, Pfizer, Ashoka Buildcon, And Inox Green Are On Stocks Watchlist ↗

August 11, 2025

Via Stocktwits

If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today ↗

August 11, 2025

Investing is about looking ahead.

Via The Motley Fool

Topics Intellectual Property

Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? ↗

August 11, 2025

It was a rare breath of fresh air for shareholders.

Via The Motley Fool

Topics Intellectual Property

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

August 11, 2025

Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.

Via Chartmill

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today ↗

August 11, 2025

The short-term picture has been less rosy than the longer-term one.

Via The Motley Fool

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply ↗

August 11, 2025

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern on board to fill in gaps.

Via Benzinga

Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk ↗

August 11, 2025

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

Via Benzinga

3 Large-Cap Stocks with Promising Prospects

August 11, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

2 Stocks to Buy With $5,000 and Hold for a Decade ↗

August 10, 2025

These two stocks come from completely different industries, but each could boost a long-term investor's returns.

Via The Motley Fool

2 Beaten-Down Stocks to Buy and Hold ↗

August 10, 2025

The market has been tough on these stocks, but a closer look at each is warranted.

Via The Motley Fool

Topics Intellectual Property

Meet the 7.3% Yield Dividend Stock That Could Soar in 2026 ↗

August 10, 2025

This stock recently bounced on strong Q2 earnings, and the fun could be just getting started.

Via The Motley Fool

Topics Government World Trade

Positive Gems Becomes the World’s Most Followed Modern Pharmaceutical Brand

August 08, 2025

Via Get News

Topics Intellectual Property

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

August 08, 2025

From Arvinas Inc.

Via GlobeNewswire

1 Safe-and-Steady Stock to Target This Week and 2 We Avoid

August 08, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pfizer (NY:PFE)

All News about Pfizer

Starting at $3.75/week.

Subscribe Today